Literature DB >> 8522715

Assessment of reverse use-dependent blocking actions of class III antiarrhythmic drugs by 24-hour Holter electrocardiography.

Y Okada1, S Ogawa, T Sadanaga, H Mitamura.   

Abstract

OBJECTIVES: This clinical study was designed to compare rate-dependent effects of class III agents on QT prolongation.
BACKGROUND: Clinical data that compare the electrophysiologic differences among class III agents with different selectivity for potassium channels are still lacking.
METHODS: QT intervals were measured over a wide range of preceding RR intervals during sinus rhythm by 24-h Holter electrocardiography before and after oral administration of four class III agents: E4031, dofetilide, MS551 and d-sotalol. Rate-dependent changes in the QT interval were assessed by the slope of the linear regression line estimating the QT-square root of RR relation.
RESULTS: All agents significantly increased the mean slope: E4031 increased the mean [+/- SD] value from 0.32 +/- 0.05 to 0.42 +/- 0.13 (p < 0.01), dofetilide from 0.32 +/- 0.03 to 0.50 +/- 0.12 (p < 0.03), MS551 from 0.35 +/- 0.06 to 0.45 +/- 0.10 (p < 0.02) and d-sotalol from 0.31 +/- 0.05 to 0.33 +/- 0.04 (p < 0.05). However, in those patients given either E4031, dofetilide or MS551, the degree of QT prolongation was smaller at shorter square root of RR intervals and was better preserved at shorter square root of RR intervals by d-sotalol, with a smaller increase in slope (p < 0.02 vs. dofetilide and MS551).
CONCLUSIONS: On ambulatory electrocardiography, reverse use dependence in QT prolongation was least prominent with d-sotalol among the four study drugs. In the range of physiologic heart rates, class III agents could manifest different profiles of rate dependence in their QT-prolonging effect.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8522715     DOI: 10.1016/0735-1097(95)00424-6

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  9 in total

1.  Frequency-dependent electrophysiological effect of ibutilide on human atrium and ventricle.

Authors:  N Oshikawa; I Watanabe; R Masaki; A Shindo; T Kojima; S Saito; Y Ozawa; K Kanmatsuse
Journal:  J Interv Card Electrophysiol       Date:  2001-03       Impact factor: 1.900

2.  Human ex-vivo action potential model for pro-arrhythmia risk assessment.

Authors:  Guy Page; Phachareeya Ratchada; Yannick Miron; Guido Steiner; Andre Ghetti; Paul E Miller; Jack A Reynolds; Ken Wang; Andrea Greiter-Wilke; Liudmila Polonchuk; Martin Traebert; Gary A Gintant; Najah Abi-Gerges
Journal:  J Pharmacol Toxicol Methods       Date:  2016-05-25       Impact factor: 1.950

3.  Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties.

Authors:  Charles Antzelevitch; Luiz Belardinelli; Andrew C Zygmunt; Alexander Burashnikov; José M Di Diego; Jeffrey M Fish; Jonathan M Cordeiro; George Thomas
Journal:  Circulation       Date:  2004-08-09       Impact factor: 29.690

4.  Machine learning plus optical flow: a simple and sensitive method to detect cardioactive drugs.

Authors:  Eugene K Lee; Yosuke K Kurokawa; Robin Tu; Steven C George; Michelle Khine
Journal:  Sci Rep       Date:  2015-07-03       Impact factor: 4.379

5.  Mitigating prolonged QT interval in cancer nanodrug development for accelerated clinical translation.

Authors:  Amalendu P Ranjan; Anindita Mukerjee; Lawrence Helson; Jamboor K Vishwanatha
Journal:  J Nanobiotechnology       Date:  2013-12-14       Impact factor: 10.435

6.  Electrophysiological Characteristics of Human iPSC-Derived Cardiomyocytes for the Assessment of Drug-Induced Proarrhythmic Potential.

Authors:  Wataru Yamamoto; Keiichi Asakura; Hiroyuki Ando; Tomohiko Taniguchi; Atsuko Ojima; Takaaki Uda; Tomoharu Osada; Seiji Hayashi; Chieko Kasai; Norimasa Miyamoto; Hiroyuki Tashibu; Takashi Yoshinaga; Daiju Yamazaki; Atsushi Sugiyama; Yasunari Kanda; Kohei Sawada; Yuko Sekino
Journal:  PLoS One       Date:  2016-12-06       Impact factor: 3.240

7.  Facilitation of I Kr current by some hERG channel blockers suppresses early afterdepolarizations.

Authors:  Kazuharu Furutani; Kunichika Tsumoto; I-Shan Chen; Kenichiro Handa; Yuko Yamakawa; Jon T Sack; Yoshihisa Kurachi
Journal:  J Gen Physiol       Date:  2019-01-23       Impact factor: 4.086

Review 8.  Mechanism of action of the new anti-ischemia drug ranolazine.

Authors:  G Hasenfuss; L S Maier
Journal:  Clin Res Cardiol       Date:  2007-11-28       Impact factor: 5.460

9.  A Computational Pipeline to Predict Cardiotoxicity: From the Atom to the Rhythm.

Authors:  Pei-Chi Yang; Kevin R DeMarco; Parya Aghasafari; Mao-Tsuen Jeng; John R D Dawson; Slava Bekker; Sergei Y Noskov; Vladimir Yarov-Yarovoy; Igor Vorobyov; Colleen E Clancy
Journal:  Circ Res       Date:  2020-02-24       Impact factor: 17.367

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.